Latest Administration News

Duxton Farms reported a significant $12.5 million net loss for FY2025, reversing last year’s profit, while declaring an 85% franked dividend of 24 cents per share. The company’s revenue dipped due to property sales and increased expenses tied to a proposed acquisition.

Trigg Minerals has acquired 100% of the Tennessee Mountain Tungsten Project in Nevada, marking a strategic expansion into critical minerals with a historically significant tungsten resource. The move aligns with rising tungsten demand and the company's goal to become a key supplier of defence metals.

AMP reported a 9.2% increase in underlying net profit after tax to $131 million for the first half of 2025, driven by robust cashflow growth and steady performances across its wealth and banking divisions. The company also declared a 2.0 cents per share interim dividend, maintaining disciplined cost control amid ongoing strategic investments.

Toys"R"Us ANZ has formalised a Deed of Company Arrangement, paving the way for Directed Electronics Australia to acquire the company and trigger its delisting from the ASX.

Finexia Financial Group has ended talks on a major disposal deal and is managing loan defaults with fresh collateral, while expanding its childcare lending strategy.

Nyrada’s Phase I clinical trial for Xolatryp™ concludes with positive safety and pharmacokinetic results, paving the way for a Phase IIa study in acute myocardial infarction patients.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

ChemX Materials Limited has explained the delayed filing of director interest notices, attributing it to transitional challenges during its recent recapitalisation and governance overhaul.

Immutep has received encouraging feedback from the FDA on its immunotherapy eftilagimod alfa combined with KEYTRUDA for patients with low PD-L1 expression in head and neck cancer, opening potential accelerated approval pathways.

Coventry Group’s FY25 results reveal a sharp EBITDA decline amid ERP disruptions and soft markets, prompting a major cost reduction drive for FY26.

Macro Metals Limited has successfully raised A$2 million through a share placement, positioning itself to accelerate exploration and expand its mining services operations.